Pre-made Vudalimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-CTLA4/CTLA-4;PDCD1/PD-1 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor’s proprietary XmAb? technology) that increases binding affinity to the receptor FcRn.
| Products Name (INN Index) | Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody |
|---|---|
| INN Name | Vudalimab |
| Target | CTLA4,PDCD1 |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Xencor |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | XmAb? bispecific platformna (For heterodimer, E357Q/S364K-L368D/K370S; For purification with PI, N208D in CH1, Q295E in CH2, and N384D, Q418E, and N421D in CH3.) |
| Previous Name | NA |
| Gm Offical Target Name | CTLA4,PDCD1 |
| Package |
